A practical reference on metabolic research: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-08-01. Anything still debated is marked as such rather than presented as settled.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Derived from a fragment of human growth hormone |
| Sequence basis | hGH residues 176-191 | Commonly described as a 16-amino-acid fragment |
| Appearance | White to off-white powder | Typical for lyophilized research peptides |
| Solubility | Soluble in water or aqueous buffer | Exact solubility depends on pH and purity |
| Common synonyms | AOD9604; hGH 176-191 | Spelling and punctuation vary across sources |
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
endocytosis Any process by which a substance is actively uptaken by or brought inside of a cell, crossing the plasma membrane from an extracellular space into an intracellular space, which includes the subclasses of pinocytosis, phagocytosis, and receptor-mediated processes. All of these involve surrounding an extracellular molecule, protein, or even another cell or organism with an extension or invagination of the cell membrane, which then "buds off" or separates from the rest of the membrane on the cytoplasmic side, forming a membrane-enclosed vesicle containing the ingested materials. By this mechanism the material can cross the lipid bilayer without being exposed to the hydrophobic space in between, instead remaining suspended in the fluid of the extracellular space. Many large, polar macromolecules which cannot simply diffuse across the membrane, such as metabolites and hormones, are transported into the cell by endocytosis. It is distinguished from alternative routes such as passing through protein channels or being chaperoned by transport proteins. The reverse process is called exocytosis.
=== Amino acid enrichment for certain functional categories of LCRs === A bioinformatics analysis of prokaryotic LCRs identified 5 types of amino acid enrichment, for certain functional categories of LCRs:
It looked terrible coming at the fag end of the recession, when the government had a tiny majority, and just after the fiasco of Black Wednesday and the scandal of David Mellor's resignation. Heseltine was attacked by Marcus Fox, Jim Pawsey, Nicholas Winterton, Bill Cash, Rhodes Boyson and his former supporter David Evans who called openly for him to be sacked. The High Court found that Heseltine and British Coal had acted "unlawfully and irrationally". Faced with likely defeat in the House of Commons, Heseltine was forced to agree to a moratorium, during which time he attempted, largely unsuccessfully, to seek new markets for British coal and to obtain government subsidies for pits. The band Chumbawamba released the critical song "Mr Heseltine meets the public" that portrayed Heseltine as an out-of-touch figure; the same group had once dedicated a song to the village of Fitzwilliam, West Yorkshire, which was reduced to a ghost village by the closure of the local coal pits. In February 1993, Heseltine announced that unlike the Dutch and Belgian governments, Britain would not be contributing to any bailout of Anglo-Dutch DAF Trucks (which in the event went bankrupt in June). By early 1993 Heseltine's fortunes were at a low ebb, with his future as a minister being called into question. A review into the pit closures appeared in March 1993. By this time, public anger had cooled. By the start of 1997, British Coal had been reduced to 28 pits.
Sources: en.wikipedia.org
Prusiner of California named the prion, and thought that the protein did not require DNA to be made; the Institute of Molecular Systems Biology of ETH Zurich, and Charles Weiss mann, who looked for a section of mRNA that could make the protein, and in 1985 found a possible section of DNA; husband and wife, Harry Baker and Ros Ridley of the MRC in London discovered in 1989 that a genetic mutation could cause the prion to be made; seventeen possible genetic mutations were found in total in the UK; children treated with human growth hormone were found, in May 1985, to have CJD; Michael Preece of the UCL Great Ormond Street Institute of Child Health in London; more cases were found in France in 1992; scrapie in sheep; remains of sheep, in cattle feed caused BSE, which was discovered in 1986; Ray Bradley, head of BSE research at the Central Veterinary Laboratory; Graham Medley, a disease modeller at Imperial College, who looked at other modes of possible transmission, than contaminated animal feed; James Kirkwood, of the Institute of Zoology in London, and infection in the greater kudu; Gordon Hunter, veterinary researcher; Hamish Chalmers of Redesdale in Northumberland, and scrapie-resistant Swaledale sheep, which were bred at the Institute for Research on Animal Diseases (now the Pirbright Institute) at Compton, Berkshire; the amyloid beta protein of dementia, and research on marmosets. Narrated by Libby Purves, directed by John Bird, produced by Mike Johnstone, made by Langham Productions
== Chemical properties == Alkanes are only weakly reactive with most chemical compounds. They only react with the strongest of electrophilic reagents by virtue of their strong C–H bonds (~100 kcal/mol) and C–C bonds (~90 kcal/mol). They are also relatively unreactive toward free radicals. This inertness is the source of the term paraffins (with the meaning here of "lacking affinity"). In crude oil the alkane molecules have remained chemically unchanged for millions of years.
Dhamara Fishing Harbour is an international standard Harbour. The Harbour is located in the North Bank of Dhamra River in the revenue village Dhamara, Dist. Bhadrak. It has become the first harbour certified by Export Inspection Agency (EIA) in the state following approval of the Export Inspection Council (EIC), India and meets the Euro standard fish food as specified by European Union. The major species landing in the jetties are (i) Pomfret (ii) Shrimps (iii) Bombay Duck (iv) Hilsha (v) Mackerel (vi) Johnius (Vii) Ribbon fish (Viii) Megalops (ix) Borei etc. These species have high demand both in National and International market. All these fish landings are maintained with proper cold chain and processed hygienically for value addition to fetch good price in the market which are regularly checked by the Harbour Authorities for maintenance of the quality.
By a misguided economy dogs are given meat scraps and tallow graves; one must avoid this, because these foods make them heavy and sick; give them twice a day a soup of coarse bread made with water, fat and the bottom of the stew pot; put a half-kilogram of bread at least in each soup. In England, care to give dogs particular food dates at least from the late eighteenth century, when The Sportsman's dictionary (1785) described the best diet for a dog's health in its article "Dog":
Sources: en.wikipedia.org
No, it is a synthetic peptide fragment corresponding to a small portion of hGH. It is not the full 191-amino-acid hormone and does not reproduce all of hGH's effects.
It is commonly described as a 16-amino-acid peptide based on residues 176-191 of human growth hormone. Some sources vary in notation, so checking the stated sequence is useful.
It is not typically described as a standalone natural hormone. The sequence is derived from the C-terminal region of human growth hormone, but the synthetic peptide is a laboratory-made construct.
AOD-9604 is a synthetic peptide fragment of human growth hormone, corresponding to amino acids 176-191. It is studied for potential effects on fat metabolism, but it is not approved as a drug in most countries. Its exact mechanism remains under investigation.